Trade Sana Biotechnology, Inc. - SANA CFD
Add to favourite- Summary
- Historical Data
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 50.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 5.39 |
Open | 5.38 |
1-Year Change | -7.08% |
Day's Range | 4.93 - 5.38 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 6, 2024 | 5.01 | -0.29 | -5.47% | 5.30 | 5.38 | 4.92 |
Sep 5, 2024 | 5.39 | -0.06 | -1.10% | 5.45 | 5.55 | 5.34 |
Sep 4, 2024 | 5.46 | -0.03 | -0.55% | 5.49 | 5.74 | 5.38 |
Sep 3, 2024 | 5.55 | -0.34 | -5.77% | 5.89 | 6.06 | 5.54 |
Aug 30, 2024 | 6.02 | -0.07 | -1.15% | 6.09 | 6.30 | 5.87 |
Aug 29, 2024 | 6.07 | 0.24 | 4.12% | 5.83 | 6.26 | 5.83 |
Aug 28, 2024 | 5.82 | 0.13 | 2.28% | 5.69 | 5.86 | 5.60 |
Aug 27, 2024 | 5.75 | 0.01 | 0.17% | 5.74 | 5.79 | 5.54 |
Aug 26, 2024 | 5.81 | -0.03 | -0.51% | 5.84 | 6.00 | 5.69 |
Aug 23, 2024 | 5.81 | 0.17 | 3.01% | 5.64 | 6.10 | 5.59 |
Aug 22, 2024 | 5.69 | 0.54 | 10.49% | 5.15 | 5.69 | 5.14 |
Aug 21, 2024 | 5.26 | 0.28 | 5.62% | 4.98 | 5.38 | 4.98 |
Aug 20, 2024 | 4.96 | 0.03 | 0.61% | 4.93 | 5.04 | 4.90 |
Aug 19, 2024 | 5.01 | 0.13 | 2.66% | 4.88 | 5.08 | 4.86 |
Aug 16, 2024 | 4.95 | 0.07 | 1.43% | 4.88 | 5.02 | 4.88 |
Aug 15, 2024 | 4.96 | 0.22 | 4.64% | 4.74 | 4.98 | 4.74 |
Aug 14, 2024 | 4.72 | -0.20 | -4.07% | 4.92 | 5.01 | 4.71 |
Aug 13, 2024 | 4.86 | -0.02 | -0.41% | 4.88 | 4.98 | 4.80 |
Aug 12, 2024 | 4.87 | -0.01 | -0.20% | 4.88 | 4.94 | 4.77 |
Aug 9, 2024 | 4.87 | 0.07 | 1.46% | 4.80 | 5.46 | 4.78 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sana Biotechnology, Inc. Company profile
About Sana Biotechnology Inc
Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Sana Biotechnology Inc revenues was not reported. Net loss increased 42% to $245.2M. Higher net loss reflects Personnel increase of 36% to $55.2M (expense), General and administrative - Balancing increase of 80% to $32.6M (expense), Stock-based Compensation in R&D increase from $2.6M to $9.9M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
188 East Blaine Street, Suite 400
SEATTLE
WASHINGTON 98102
US
News
![](https://img.capital.com/imgs/articles/192x130x1/1350x880_-HP-_Newsquawk-light.png)
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Gold_10.jpg)
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024![](https://img.capital.com/imgs/articles/192x130x1/USUK.jpg)
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024![](https://img.capital.com/imgs/articles/192x130x1/European-stocks_0.jpg)
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Global-selloff_0.jpg)
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Graphiccs-1-.png)
FOMC PREVIEW
Markets believe the Federal reserve will continue to leave their monetary policy unchanged at the meeting next week.
14:09, 1 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com